Illumina, Inc.

NASDAQ:ILMN

Medical - Diagnostics & Research

Healthcare
$210.01 +1.23%

+$1.95 today

Market cap
$31.75B
Beta
1.49
P/E (TTM)
28.9
EPS (TTM)
$5.58
52W Low $88.00High $177.22

Volume 1.63M

Average 1.65M

ILMN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Illumina, Inc.NASDAQ: ILMN

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) declines year over year

Q2 FY2026 weighted avg shares (diluted) of 153M shares fell 2.5% year over year, ahead of the -3.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -2.5% holds above the trailing-twelve-month pace of -3.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
153M-0.6% QoQ
Last fiscal yearDec 2025
156M-1.9% YoY
LTMJun 2026
153.75M-3.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.5%——
1 year-1.9%——
3-year CAGR-0.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
156M USD
Year-over-year change
-1.9%
4-year CAGR
+0.8%

Weighted Avg Shares (Diluted) vs competitors

How ILMN compares with its peers on the latest reported figures

  • ILMN's LTM Jun 2026 weighted avg shares (diluted) of 153.75M shares is the 2nd highest of the 11 companies compared; the peer median is 111.23M shares.
  • Its year-over-year change of -3.3% is the lowest of 11, against a peer median of +4.8%.
  • Over three fiscal years its annual growth of -0.2% compares with a peer median of +7.1%.
ILMN Competitors Peer median
Weighted Avg Shares (Diluted) for ILMN and competitors
Company Period LTM YoY 3-year CAGR
PACBPacific Biosciences of California, Inc.LTM Mar 2026302.18M +5.2%+10.1%
ILMNIllumina, Inc.LTM Jun 2026153.75M -3.3%-0.2%
NTRANatera, Inc.LTM Jun 2026139.67M +7.5%+11.6%
GHGuardant Health, Inc.LTM Sep 2026131.61M +5.9%+7.1%
NEONeoGenomics, Inc.LTM Jun 2026129.14M +1.5%+1.0%
TXG10x Genomics, Inc.LTM Sep 2026129.04M +4.4%+3.1%
PSNLPersonalis, Inc.LTM Mar 202693.42M +36.5%+25.0%
MYGNMyriad Genetics, Inc.LTM Mar 202693.15M +2.4%+5.0%
SOPHSOPHiA GENETICS S.A.LTM Mar 202668.62M +3.6%+1.8%
BLLNBillionToOne, Inc.LTM Jun 202649.5M +10.7%—
WGSGeneDx Holdings Corp.LTM Jun 202628.68M +2.4%+38.0%
Peer median (excluding ILMN) 111.23M+4.8%+7.1%

Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.53B4.58B4.5B4.37B4.34B
Cost of Revenue1.37B1.61B1.76B1.51B1.45B
Gross Profit3.15B2.97B2.74B2.86B2.89B
Gross Margin69.7%64.8%60.9%65.4%66.7%
Research & Development1.19B1.32B1.35B1.17B951M
Selling, General & Admin2.09B1.3B1.61B1.09B1.08B
Operating Expenses3.28B7.15B3.81B3.69B2.03B
Depreciation & Amortization251M394M432M354M270M
EBITDA1.2B(3.92B)(608M)(725M)1.46B
EBITDA Margin26.4%-85.4%-13.5%-16.6%33.6%
Operating Income(123M)(4.18B)(1.07B)(833M)864M
Operating Margin-2.7%-91.2%-23.7%-19.1%19.9%
Interest Income011M58M46M40M
Interest Expense61M26M77M100M101M
Other Income / Expenses1.01B(157M)(48M)(346M)222M
Income Before Tax884M(4.34B)(1.12B)(1.18B)1.09B
Pre-Tax Margin19.5%-94.6%-24.8%-27.0%25.0%
Income Tax Expense122M68M44M44M236M
Net Income762M(4.4B)(1.16B)(1.22B)850M
Net Margin16.8%-96.1%-25.8%-28.0%19.6%
EPS (Basic)5.08(28.05)(7.35)(7.69)5.48
EPS (Diluted)5.05(28.05)(7.35)(7.69)5.45
Weighted Avg Shares150M157M158M159M155M
Weighted Avg Shares (Diluted)151M157M158M159M156M

Illumina, Inc.

NASDAQ:ILMN

Intrinsic Alpha fair value

Locked

Current Price

$210.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.